Cytek Biosciences, Inc.
CTKB
$3.64
$0.041.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 265.61M | 277.86M | 277.78M | 277.21M | 270.09M |
| Total Receivables | 55.21M | 60.59M | 52.66M | 44.75M | 50.37M |
| Inventory | 45.65M | 44.01M | 46.86M | 50.12M | 54.93M |
| Prepaid Expenses | 4.37M | 4.64M | 3.15M | 2.80M | 4.61M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 9.67M | 9.35M | 9.76M | 9.20M | 8.66M |
| Total Current Assets | 380.50M | 396.45M | 390.19M | 384.08M | 388.65M |
|
|
|||||
| Total Current Assets | 380.50M | 396.45M | 390.19M | 384.08M | 388.65M |
| Net Property, Plant & Equipment | 27.70M | 28.13M | 28.63M | 27.44M | 28.20M |
| Long-term Investments | 16.68M | 16.66M | 16.18M | 16.18M | 16.18M |
| Goodwill | 16.68M | 16.66M | 16.18M | 16.18M | 16.18M |
| Total Other Intangibles | 19.43M | 20.13M | 20.49M | 21.42M | 22.25M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 36.68M | 36.53M | 34.13M | 34.60M | 35.19M |
| Total Assets | 482.60M | 499.50M | 491.23M | 483.73M | 492.07M |
|
|
|||||
| Total Accounts Payable | 6.25M | 5.53M | 5.39M | 3.19M | 3.73M |
| Total Accrued Expenses | 19.75M | 21.69M | 20.12M | 14.38M | 16.88M |
| Short-term Debt | 2.40M | 4.16M | -- | -- | 1.40M |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 5.13M | 4.26M | 5.53M | 4.33M | 2.82M |
| Total Finance Division Other Current Liabilities | 34.16M | 32.03M | 31.76M | 30.48M | 30.75M |
| Total Other Current Liabilities | 34.16M | 32.03M | 31.76M | 30.48M | 30.75M |
| Total Current Liabilities | 67.69M | 67.66M | 62.80M | 52.38M | 55.57M |
|
|
|||||
| Total Current Liabilities | 67.69M | 67.66M | 62.80M | 52.38M | 55.57M |
| Long-Term Debt | 918.00K | 1.05M | 1.24M | 1.33M | 1.48M |
| Short-term Debt | 2.40M | 4.16M | -- | -- | 1.40M |
| Capital Leases | 7.45M | 7.55M | 7.76M | 8.11M | 8.70M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 26.92M | 27.50M | 33.97M | 32.78M | 33.71M |
| Total Liabilities | 102.97M | 103.76M | 105.76M | 94.60M | 99.45M |
|
|
|||||
| Common Stock & APIC | 426.83M | 430.92M | 430.20M | 435.10M | 429.52M |
| Retained Earnings | -46.60M | -35.20M | -44.84M | -45.78M | -35.35M |
| Treasury Stock & Other | -609.00K | 16.00K | 101.00K | -195.00K | -1.55M |
| Total Common Equity | 379.62M | 395.74M | 385.46M | 389.12M | 392.61M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 379.62M | 395.74M | 385.46M | 389.12M | 392.61M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 379.62M | 395.74M | 385.46M | 389.12M | 392.61M |
|
|
|||||